UTHR — United Therapeutics Cashflow Statement
0.000.00%
- $13.09bn
- $10.12bn
- $2.88bn
- 100
- 69
- 64
- 92
Annual cashflow statement for United Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 515 | 476 | 727 | 985 | 1,195 |
Depreciation | |||||
Non-Cash Items | 131 | 247 | 165 | 37.8 | 120 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 59.7 | -174 | -141 | -97.8 | -60.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 756 | 598 | 803 | 978 | 1,327 |
Capital Expenditures | -59.3 | -121 | -139 | -230 | -247 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -679 | -366 | -673 | -489 | 664 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -739 | -487 | -812 | -720 | 417 |
Financing Cash Flow Items | -5.4 | -10.8 | -18.9 | -16.5 | -14.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -16.9 | 44.8 | 75.4 | -11.9 | -1,255 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.3 | 156 | 66.4 | 247 | 490 |